• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Hyderus

Hyderus Cyf and Hyderus Teoranta

Pandemicast
  • Home
  • Tell the Truth
    • Videos
  • About us
    • Access to innovative medicines
    • New Work in India
    • Mark Chataway
    • We pay our taxes
    • Our approach to managing risk perception and crises
    • African journalists we respect
  • Customers
  • Expertise
    • Development and Politics
      • Assessing science policy in 48 African countries
      • The future of European development funding
      • The link between family planning and climate change
      • What are the influence networks in health?
    • Knowledge Transfer and Capacity Building
      • For senior executives
      • For the online world
      • To manage international politics
    • Public Health
      • Drivers and barriers for new vaccines
    • Strategic Planning
      • Avoiding a crisis in the Middle East
      • Developing BRICS countries as donors
      • For an international organisation in India
      • Increasing immunization coverage in central India
      • Setting up systems for issues management
    • Treatment Decisions
      • How to get healthcare systems to care for older women
      • Immunisation for adults
      • Stakeholders and corporate social responsibility
  • Contact
  • Blog
    • What we’re thinking
    • Our World
    • Staff blog
  • Flexible Pricing Plan

Alzheimer's disease

Parkinson’s and the difficulty of treating neurological conditions

June 28, 2019 by Nicholas Parry Leave a Comment

Image ID: 33194756 (L)

Neurological conditions such as Parkinson’s disease and Alzheimer’s disease have long evaded satisfactory treatment. Despite the best efforts and the investment of billions by pharmaceutical companies, they continue to pose threats to public health - especially as life expectancies around the world increase and exposure to risk factors such as … [Read more...] about Parkinson’s and the difficulty of treating neurological conditions

Filed Under: Featured, Our craft, Staff blog Tagged With: Alzheimer's disease, neurological disease, Parkinson's disease

Axovant fails while Pfizer leaves – the grim outlook of Alzheimer’s research

February 26, 2018 by Nicholas Parry Leave a Comment

In yet another setback to the treatment of Alzheimer’s disease, Axovant Sciences has announced that their latest attempt at creating a treatment - a drug known as Intepirdine (a (5-HT)6 receptor antagonist) - has failed during late stage clinical trials. Meanwhile, pharmaceutical giant Pfizer Inc has announced plans to leave the field of … [Read more...] about Axovant fails while Pfizer leaves – the grim outlook of Alzheimer’s research

Filed Under: Featured, Staff blog Tagged With: Alzheimer's disease, Axovant, Pfizer

Immunotherapy: the future of Alzheimer’s research?

February 16, 2018 by Nicholas Parry Leave a Comment

Alzheimer’s research may see a well needed boost in the form of a research deal funded by Chicago based pharmaceutical group AbbVie. The recipient research group, Alector, is  to receive a $205 million USD up front payment, as well as future equity investments worth up to $20 million. Alector has seen a great deal of interest within the … [Read more...] about Immunotherapy: the future of Alzheimer’s research?

Filed Under: Featured, Staff blog Tagged With: Alector, Alzheimer's disease, Amgen, amyloid, Axovant, Merck & CO Inc, Pfizer

Failed trials for Alzheimer’s may mean a key theory is wrong

February 26, 2017 by Nicholas Parry 1 Comment

Copyright:a'>olganikitina / 123RF Stock Photo

A drug trial for a Merck & Co Inc. (MSD) medication verubecestat has been stopped because it was very unlikely to show a significant difference in Alzheimers disease progression compared to a placebo control. This was a phase III clinical trial in patients with early dementia. The setback comes after months of positive media attributed … [Read more...] about Failed trials for Alzheimer’s may mean a key theory is wrong

Filed Under: Featured, Staff blog Tagged With: Alzheimer's disease, amyloid hypothesis

Primary Sidebar

Categories

  • Featured (206)
  • Our craft (22)
  • Staff blog (56)
access to medicines Africa Chris Nial climate change communications consultancy coronavirus COVID-19 Development Donald Trump environment foreign policy Global Health Progress global warming green energy health healthcare health policy HIV Hyderus india Mark Chataway ODA PandemiCast patents pharmaceutical industry public health vaccination vaccines wales WHO

Hyderus on Twitter

Tweets by Hyderus

Hyderus on Facebook

Videos

The Three Commitments
Why Consultants end up not telling the truth
The worst kind of market research interviewing technique ever
Why bright people can’t explain themselves
More videos

Clients

 
 
 

Footer

Looking For?

  • Our World
  • Contact us
  • Privacy Policy
  • Terms of use

Recent Posts

  • Accessible healthcare could aid climate crisis in rainforest communities
  • Climate change impact has the potential to regress cancer progress through healthcare disruption, according to study
  • Vaccines and COVID-19: Frans van den Boom speaks to Hyderus and Baird’s CMC

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Copyright © 2021 Hyderus. All rights reserved. Sitemap

  • Home
  • Tell the Truth
    ▼
    • Videos
  • About us
    ▼
    • Access to innovative medicines
    • New Work in India
    • Mark Chataway
    • We pay our taxes
    • Our approach to managing risk perception and crises
    • African journalists we respect
  • Customers
  • Expertise
    ▼
    • Development and Politics
      ▼
      • Assessing science policy in 48 African countries
      • The future of European development funding
      • The link between family planning and climate change
      • What are the influence networks in health?
    • Knowledge Transfer and Capacity Building
      ▼
      • For senior executives
      • For the online world
      • To manage international politics
    • Public Health
      ▼
      • Drivers and barriers for new vaccines
    • Strategic Planning
      ▼
      • Avoiding a crisis in the Middle East
      • Developing BRICS countries as donors
      • For an international organisation in India
      • Increasing immunization coverage in central India
      • Setting up systems for issues management
    • Treatment Decisions
      ▼
      • How to get healthcare systems to care for older women
      • Immunisation for adults
      • Stakeholders and corporate social responsibility
  • Contact
  • Blog
    ▼
    • What we’re thinking
    • Our World
    • Staff blog
  • Flexible Pricing Plan

Cookies

This site uses cookies: Find out more.